Intuitive Surgical (NASDAQ:ISRG) Stock: Insider Gary Guthart Sells 20,095 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Gary Guthart sold 20,095 shares of the company’s stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $451.61, for a total value of $9,075,102.95. Following the completion of the transaction, the director owned 1,204,530 shares of the company’s stock, valued at $543,977,793.30. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $1.61 during mid-day trading on Monday, reaching $450.68. The company’s stock had a trading volume of 1,803,848 shares, compared to its average volume of 2,427,984. The company’s fifty day simple moving average is $395.50 and its two-hundred day simple moving average is $408.83. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The stock has a market cap of $156.22 billion, a P/E ratio of 54.50, a P/E/G ratio of 3.12 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.40 EPS. Sell-side analysts expect that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ISRG. KeyCorp reaffirmed an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. BTIG Research reissued a “buy” rating and set a $454.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Truist Financial dropped their price objective on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $500.00 target price on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Finally, JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $450.00 to $475.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $493.54.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds have recently bought and sold shares of ISRG. Plato Investment Management Ltd acquired a new stake in shares of Intuitive Surgical during the second quarter worth approximately $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Intuitive Surgical in the second quarter worth $14,316,000. Hikari Power Ltd bought a new stake in shares of Intuitive Surgical in the second quarter worth $5,619,000. NewEdge Advisors LLC raised its holdings in Intuitive Surgical by 19.1% in the second quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider’s stock valued at $20,212,000 after acquiring an additional 8,142 shares in the last quarter. Finally, Nykredit A S acquired a new stake in Intuitive Surgical in the second quarter valued at $48,464,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.